Citations (77)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Alessandra Alciati, Marco Di Carlo, Cesare Siragusano, Antonino Palumbo, Ignazio Francesco Masala & Fabiola Atzeni. (2022) Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis. Expert Opinion on Biological Therapy 22:10, pages 1311-1322.
Read now
Read now
Joyce Leman, Shernaz Walton, Alison M. Layton, Kathleen A. Ward, Sandy McBride, Sandeep Cliff, Anthony Downs, Margarita Landeira & Anthony Bewley. (2020) The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study. Journal of Dermatological Treatment 31:3, pages 213-221.
Read now
Read now
Jillian Frieder, Dario Kivelevitch, Connie Tran Fiore, Saadeddine Saad & Alan Menter. (2018) The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis. Expert Review of Clinical Immunology 14:1, pages 1-19.
Read now
Read now
Michael Abrouk, M. Nakamura, T. H. Zhu, B. Farahnik, J. Koo & T. Bhutani. (2017) The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. Journal of Dermatological Treatment 28:6, pages 488-491.
Read now
Read now
Danielle Nicolazzo, Franz Kerdel & Francisco Kerdel. (2014) Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis. Psoriasis: Targets and Therapy 4, pages 11-18.
Read now
Read now
Shima Safikhani, Murali Sundaram, Yanjun Bao, Parvez Mulani & Dennis A. Revicki. (2013) Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis. Journal of Dermatological Treatment 24:1, pages 50-59.
Read now
Read now
Shumpei Yokota, Tomoyuki Imagawa, Takuji Murata, Minako Tomiita, Yasuhiko Itoh, Satoshi Fujikawa, Syuji Takei & Masaaki Mori. (2012) Guidance on the use of adalimumab for juvenile idiopathic arthritis in Japan. Modern Rheumatology 22:4, pages 491-497.
Read now
Read now
Kristian Reich, Brad Schenkel, Ning Zhao, Philippe Szapary, Matthias Augustin, Marc Bourcier, Lyn Guenther & Richard G. Langley. (2011) Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2. Journal of Dermatological Treatment 22:6, pages 337-347.
Read now
Read now
Ronald Prussick. (2010) Biologic therapies for psoriasis: do we use them enough?. Expert Review of Dermatology 5:5, pages 497-499.
Read now
Read now
Gérald E Piérard, Claudine Piérard-Franchimont, Grégory Szepetiuk, Philippe Paquet & Pascale Quatresooz. (2010) The therapeutic potential of TNF-α antagonists for skin psoriasis comorbidities. Expert Opinion on Biological Therapy 10:8, pages 1197-1208.
Read now
Read now
Ala Iaconi, Steven R Feldman & Rajesh Balkrishnan. (2010) Psoriasis and its treatment with adalimumab. Expert Opinion on Biological Therapy 10:1, pages 133-152.
Read now
Read now
Jochen Schmitt & Gottfried Wozel. (2009) Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics: Targets and Therapy 3, pages 303-318.
Read now
Read now
Abby S. Van Voorhees & Richard Fried. (2009) Depression and Quality of Life in Psoriasis. Postgraduate Medicine 121:4, pages 154-161.
Read now
Read now
Richard B Warren & Christopher EM Griffiths. (2009) Adalimumab for the treatment of psoriasis. Expert Review of Dermatology 4:1, pages 15-21.
Read now
Read now
Articles from other publishers (63)
Emilie Sbidian, Anna Chaimani, Robin Guelimi, Ignacio Garcia-Doval, Camille Hua, Carolyn Hughes, Luigi Naldi, Maria Kinberger, Sivem Afach & Laurence Le Cleach. (2023) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews 2023:7.
Crossref
Crossref
Diamant Thaçi, Ron Vender, Menno A de Rie, Curdin Conrad, David M Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Wang, Cynthia Madden, Dirk de Cuyper & Alexa B Kimball. (2023) Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. British Journal of Dermatology 188:1, pages 22-31.
Crossref
Crossref
Dong Hyun Kim, Sang Wook Son, Ki-Heon Jeong, Jiyoung Ahn, Eun-So Lee, Il-Hwan Kim, Un Ha Lee, Hai-Jin Park, Joo Yeon Ko, Byung-Soo Kim, Jin Ju Kim, Javed Rashid & Kwang Joong Kim. (2023) Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study). Annals of Dermatology 35:2, pages 107.
Crossref
Crossref
L. Guenther, A. Takhar, M. Megna, M. Sebastian, N. Nyholm, H. Thoning & L.‐Å. Levin. (2022) Impact of fixed‐dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52‐week randomized, double‐blind, PSO‐LONG trial. Journal of the European Academy of Dermatology and Venereology 36:7, pages 1054-1063.
Crossref
Crossref
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Liz Doney, Corinna Dressler, Camille Hua, Carolyn Hughes, Luigi Naldi, Sivem Afach & Laurence Le Cleach. (2022) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews 2022:8.
Crossref
Crossref
Clara Chan, Setareh Ziai, Varun Myageri, James G Burns & C Lisa Prokopich. (2021) Economic burden and loss of quality of life from dry eye disease in Canada. BMJ Open Ophthalmology 6:1, pages e000709.
Crossref
Crossref
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Liz Doney, Corinna Dressler, Camille Hua, Carolyn Hughes, Luigi Naldi, Sivem Afach & Laurence Le Cleach. (2021) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews 2021:12.
Crossref
Crossref
Andrew Blauvelt, Craig L. Leonardi, Norman Gaylis, Julia Jauch-Lembach, Alison Balfour, Lena Lemke, Sohaib Hachaichi, Ines Brueckmann, Teodora Festini & Piotr Wiland. (2021) Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS). BioDrugs 35:2, pages 229-238.
Crossref
Crossref
Anna Karpińska-Mirecka, Joanna Bartosińska & Dorota Krasowska. (2020) The effects of selected biologics and a small molecule on Health-Related Quality of Life in adult plaque psoriasis patients: A systematic review and meta-analysis. PLOS ONE 15:12, pages e0241604.
Crossref
Crossref
Matthias Augustin, Jo Lambert, Carla Zema, Elizabeth H. Z. Thompson, Min Yang, Eric Q. Wu, Viviana Garcia-Horton, Ziqian Geng, Joaquin M. Valdes, Avani Joshi & Kenneth B. Gordon. (2020) Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis. JAMA Dermatology 156:12, pages 1344.
Crossref
Crossref
Richard G. B. Langley, Kristian Reich, Vibeke Strand, Steven R. Feldman, Carle Paul, Kenneth Gordon, Richard B. Warren, Darryl Toth, Enkeleida Nikaï, Baojin Zhu, Orin Goldblum, Emily Edson-Heredia, Hilde Carlier, Russel Burge, Chen-Yen Lin, Kristin Hollister & Matthias Augustin. (2019) Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Quality of Life Research 29:2, pages 369-380.
Crossref
Crossref
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Liz Doney, Corinna Dressler, Camille Hua, Carolyn Hughes, Luigi Naldi, Sivem Afach & Laurence Le Cleach. (2020) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Megan H. Noe, Marilyn T. Wan, Daniel B. Shin, April W. Armstrong, Kristina Callis Duffin, Zelma C. Chiesa Fuxench, Robert E. Kalb, Alan Menter, Eric L. Simpson, Junko Takeshita, Stephen K. Tyring, Abby S. Van Voorhees, Nehal N. Mehta & Joel M. Gelfand. (2019) Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. Journal of the American Academy of Dermatology 81:4, pages 923-930.
Crossref
Crossref
B. Elewski, A.F. Alexis, M. Lebwohl, L. Stein Gold, D. Pariser, J. Del Rosso & G. Yosipovitch. (2019) Itch: an under‐recognized problem in psoriasis. Journal of the European Academy of Dermatology and Venereology 33:8, pages 1465-1476.
Crossref
Crossref
Inger Marie Skoie, Ingvild Dalen & Roald Omdal. (2019) Effect of Biological Treatment on Fatigue in Psoriasis: A Systematic Review and Meta-Analysis. American Journal of Clinical Dermatology 20:4, pages 493-502.
Crossref
Crossref
Marcelo Arnone, Maria Denise Fonseca Takahashi, André Vicente Esteves de Carvalho, Wanderley Marques Bernardo, Aline Lopes Bressan, Andrea Machado Coelho Ramos, Aripuanã Cobério Terena, Cacilda da Silva Souza, Daniel Holthausen Nunes, Maria Cecília de Carvalho Bortoletto, Maria de Fátima Santos Paim de Oliveira, Jane Marcy Neffá, Luciana Cristina Fieri, Luna Azulay-Abulafia, Paulo Antônio Oldani Felix, Renata Ferreira Magalhaes, Ricardo Romiti & Tatiana Jerez Jaime. (2019) Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology. Anais Brasileiros de Dermatologia 94:2 suppl 1, pages 76-107.
Crossref
Crossref
Marcelo Arnone, André Vicente Esteves de Carvalho, Maria Denise Fonseca Takahashi & Wanderley M Bernardo. (2019) Psoriasis in moderate grave plaque - immunobiological treatment. Revista da Associação Médica Brasileira 65:4, pages 493-508.
Crossref
Crossref
Julie E. Stein, Jeffrey Patterson-Fortin & Benjamin E. Bodnar. (2018) Anti-TNF therapy-induced lupus erythematosus-like syndrome in a patient treated with adalimumab for cutaneous psoriasis. BMJ Case Reports, pages bcr-2017-223473.
Crossref
Crossref
Kim A. Papp, Min Yang, Murali Sundaram, John Jarvis, Keith A. Betts, Yanjun Bao & James E. Signorovitch. (2018) Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials. Value in Health 21:1, pages 1-8.
Crossref
Crossref
Chloé Théréné, Emilie Brenaut, Thomas Barnetche & Laurent Misery. (2018) Efficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis. Journal of Investigative Dermatology 138:1, pages 38-45.
Crossref
Crossref
Boni E. Elewski, Martin M. Okun, Kim Papp, Christopher S. Baker, Jeffrey J. Crowley, Gérard Guillet, Murali Sundaram, Yves Poulin, Yihua Gu, Ziqian Geng, David A. Williams & Phoebe A. Rich. (2018) Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. Journal of the American Academy of Dermatology 78:1, pages 90-99.e1.
Crossref
Crossref
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi, Olivier Chosidow & Laurence Le Cleach. (2017) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Iltefat H. Hamzavi, Murali Sundaram, Cynthia Nicholson, Marko Zivkovic, Angela Parks-Miller, Jianyi Lee, Jingbo Yi, Yihua Gu, Martin M. Okun, Arijit Ganguli & Steve R. Arikian. (2017) Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa. Journal of the American Academy of Dermatology 77:6, pages 1038-1046.
Crossref
Crossref
April W. Armstrong, Emily Edson-Heredia, Baojin Zhu, Enkeleida Nikaï, Orin Goldblum, Kristin Hollister, James Russell, Michael Siegel & Mark Lebwohl. (2017) Burden of Psoriasis as Reported in a Cross-Sectional Study: Association of Psoriasis Severity with Health-Related Quality of Life, Depression, and Work Productivity. Journal of Psoriasis and Psoriatic Arthritis 2:4, pages 106-112.
Crossref
Crossref
L. Lazzeri, L. Pescitelli, L. Tripo, F. Ricceri & F. Prignano. (2017) Reduction in psoriasis related pruritus during biologic therapy*. Dermatologic Therapy 30:3, pages e12442.
Crossref
Crossref
F.M. Ali, A.C. Cueva, J. Vyas, A.A. Atwan, M.S. Salek, A.Y. Finlay & V. Piguet. (2017) A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. British Journal of Dermatology 176:3, pages 577-593.
Crossref
Crossref
April W. Armstrong, Delfina Guadalupe Villanueva Quintero, Cristina M. Echeverría, Yihua Gu, Mahinda Karunaratne & Ofelia Reyes Servín. (2016) Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab. American Journal of Clinical Dermatology 17:6, pages 691-699.
Crossref
Crossref
Mio Nakamura, Tian Hao Zhu, Michael Abrouk, Benjamin Farahnik, Rasnik Singh, Kristina Lee, John Koo & Tina Bhutani. (2016) Improvement in Quality of Life in Patients with Moderate to Severe Psoriasis Treated with Adalimumab or Ustekinumab. Journal of Psoriasis and Psoriatic Arthritis 1:4, pages 161-166.
Crossref
Crossref
A. Tsianakas & U. Mrowietz. (2016) Pruritus bei PsoriasisPruritus in psoriasis. Der Hautarzt 67:8, pages 601-605.
Crossref
Crossref
Bruce E. Strober, Robert Bissonnette, David Fiorentino, Alexa B. Kimball, Luigi Naldi, Neil H. Shear, Kavitha Goyal, Steven Fakharzadeh, Stephen Calabro, Wayne Langholff, Yin You, Claudia Galindo, Seina Lee & Mark G. Lebwohl. (2016) Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). Journal of the American Academy of Dermatology 74:5, pages 851-861.e4.
Crossref
Crossref
Sarah Elyoussfi, Benjamin J. Thomas & Coziana Ciurtin. (2016) Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. Rheumatology International 36:5, pages 603-612.
Crossref
Crossref
Kuzma Khobzey, Iryna Liskova, Andrea Szegedi, Lev Pavlovsky, Tomaž Lunder, Külli Kingo, Jovan Miljković, Juraj Péč, Maša Bohinc & Maja Hojnik. (2017) Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice. Acta Dermatovenerologica Alpina Pannonica et Adriatica 26:1.
Crossref
Crossref
Jacqueline Moreau, Erica Bromberg & Laura Korb Ferris. 2016. Psoriatic Arthritis and Psoriasis. Psoriatic Arthritis and Psoriasis
281
294
.
Celeste B. Burness & Kate McKeage. (2015) Adalimumab: A Review in Chronic Plaque Psoriasis. Drugs 75:18, pages 2119-2130.
Crossref
Crossref
M. Maoua, O. El Maalel, W. Boughattas, H. Kalboussi, N. Ghariani, R. Nouira, J. Zili, M. Denguezli & N. Mrizak. (2015) Qualité de vie et activité professionnelle des patients atteints de psoriasis au centre tunisien. Archives des Maladies Professionnelles et de l'Environnement 76:5, pages 439-448.
Crossref
Crossref
U. Mrowietz, E.N. Chouela, L. Mallbris, D. Stefanidis, V. Marino, R. Pedersen & R. L. Boggs. (2015)
Pruritus and quality of life in moderate-to-severe plaque psoriasis:
post hoc
explorative analysis from the PRISTINE study
. Journal of the European Academy of Dermatology and Venereology 29:6, pages 1114-1120.
Crossref
Crossref
I.M. Skoie, T. Ternowitz, G. Jonsson, K. Norheim & R. Omdal. (2015) Fatigue in psoriasis: a phenomenon to be explored. British Journal of Dermatology 172:5, pages 1196-1203.
Crossref
Crossref
Antoinette I.M. van Laarhoven, Ineke M. van der Sman-Mauriks, A. Rogier T. Donders, Mathilde C. Pronk, Peter C.M. van de Kerkhof & Andrea W.M. Evers. (2015) Placebo Effects on Itch: A Meta-Analysis of Clinical Trials of Patients with Dermatological Conditions. Journal of Investigative Dermatology 135:5, pages 1234-1243.
Crossref
Crossref
K.B. Gordon, A.B. Gottlieb, R.G. Langely, P. Kerkhof, K.T. Belasco, M. Sundaram, M. Okun & L. Serra. (2014) Adalimumab retreatment successfully restores clinical response and health‐related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. Journal of the European Academy of Dermatology and Venereology 29:4, pages 767-776.
Crossref
Crossref
K.A. Papp, M. Sundaram, Y. Bao, D.A. Williams, Y. Gu, J.E. Signorovitch, Y. Wang, J.M. Valdes & P.M. Mulani. (2014) Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. Journal of the European Academy of Dermatology and Venereology 28:6, pages 790-798.
Crossref
Crossref
Jérémy Lambert, Brian B. Hansen, Benoit Arnould, Géraldine Grataloup, Isabelle Guillemin, Lise Højbjerre, Martin Strandberg-Larsen & Margaret C. Reilly. (2014) Linguistic Validation into 20 Languages and Content Validity of the Rheumatoid Arthritis-Specific Work Productivity and Activity Impairment Questionnaire. The Patient - Patient-Centered Outcomes Research 7:2, pages 171-176.
Crossref
Crossref
P.L. Mattei, K.C. Corey & A.B. Kimball. (2014) Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. Journal of the European Academy of Dermatology and Venereology 28:3, pages 333-337.
Crossref
Crossref
Charlotte D'Mello, Kiarash Riazi, Tai Le, Katarzyna M. Stevens, Arthur Wang, Derek M. McKay, Quentin J. Pittman & Mark G. Swain. (2013) P-Selectin-Mediated Monocyte–Cerebral Endothelium Adhesive Interactions Link Peripheral Organ Inflammation To Sickness Behaviors. The Journal of Neuroscience 33:37, pages 14878-14888.
Crossref
Crossref
Christine S. Ahn, Cheryl J. Gustafson, Laura F. Sandoval, Scott A. Davis & Steven R. Feldman. (2013) Cost Effectiveness of Biologic Therapies for Plaque Psoriasis. American Journal of Clinical Dermatology 14:4, pages 315-326.
Crossref
Crossref
Maike Mose, Zhanyuan Kang, Line Raaby, Lars Iversen & Claus Johansen. (2013) TNFα- and IL-17A-mediated S100A8 expression is regulated by p38 MAPK. Experimental Dermatology 22:7, pages 476-481.
Crossref
Crossref
Cassyano Januário Correr, Inajara Rotta, Thaís de Souza Teles, Rangel Ray Godoy, Bruno Salgado Riveros, Mariana Martins Garcia, Patrícia Rodrigues Gonçalves & Michel Fleith Otuki. (2013) Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials. Cadernos de Saúde Pública 29:suppl 1, pages s17-s31.
Crossref
Crossref
B.E. StroberJ.M. SobellK.C. DuffinY. BaoA. GuérinH. YangO. GoldblumM.M. OkunP.M. Mulani. (2012) Sleep quality and other patient‐reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open‐label Phase IIIB trial. British Journal of Dermatology 167:6, pages 1374-1381.
Crossref
Crossref
Erica L. Baker, Craig I. Coleman, Kurt M. Reinhart, Olivia J. Phung, Lisa Kugelman, Wendy Chen, C. Michael White, Carla M. Mamolo, Joseph C. Cappelleri & William L. Baker. (2012) Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses. Dermatology and Therapy 2:1.
Crossref
Crossref
Rodrigo Valdes-Rodriguez, Shawn G. Kwatra & Gil Yosipovitch. (2018) Itch in Psoriasis: From Basic Mechanisms to Practical Treatments. Psoriasis Forum 18a:3, pages 110-117.
Crossref
Crossref
Alexa Boer Kimball, Andrew P. Yu, James Signorovitch, Jipan Xie, Magda Tsaneva, Shiraz R. Gupta, Yanjun Bao & Parvez M. Mulani. (2012) The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology 66:2, pages e67-e76.
Crossref
Crossref
Georgia Avgerinou, Dimitris Tousoulis, Gerasimos Siasos, Evaggelos Oikonomou, Konstantinos Maniatis, Nikolaos Papageorgiou, Theodoros Paraskevopoulos, Antigoni Miliou, Dimitra Koumaki, George Latsios, Anastasia Therianiou, Athanasios Trikas, Anna Maria Kampoli & Christodoulos Stefanadis. (2011) Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. International Journal of Cardiology 151:3, pages 382-383.
Crossref
Crossref
Bruce E. Strober, Yves Poulin, Francisco A. Kerdel, Richard G. Langley, Yihua Gu, Shiraz R. Gupta, Martin M. Okun & Kim A. Papp. (2011) Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study. Journal of the American Academy of Dermatology 64:4, pages 671-681.
Crossref
Crossref
Alexa B. Kimball, Arielle G. Bensimon, Annie Guerin, Andrew P. Yu, Eric Q. Wu, Martin M. Okun, Yanjun Bao, Shiraz R. Gupta & Parvez M. Mulani. (2011) Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities. American Journal of Clinical Dermatology 12:1, pages 51-62.
Crossref
Crossref
Kim A. Papp, James Signorovitch, Karthik Ramakrishnan, Andrew P. Yu, Shiraz R. Gupta, Yanjun Bao & Parvez M. Mulani. (2011) Effects of Adalimumab versus Placebo on Risk of Symptom Worsening in Psoriasis and Subsequent Impacts on Health-Related Quality-of-Life. Clinical Drug Investigation 31:1, pages 51-60.
Crossref
Crossref
Tina Bhutani, Tejas Patel & Bonnie Koo. (2018) Adalimumab Treatment and Work Productivity in Patients with Moderate to Severe Psoriasis: Results from a Prospective Clinical Trial. Psoriasis Forum 16a:4, pages 2-6.
Crossref
Crossref
Alice Gottlieb, JingYuan Feng, David J. Harrison & Denise Globe. (2010) Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology 63:4, pages 580-586.
Crossref
Crossref
Alan Menter, Kenneth B. Gordon, Craig L. Leonardi, Yihua Gu & Orin M. Goldblum. (2010) Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology 63:3, pages 448-456.
Crossref
Crossref
L. Soegaard-Madsen, C. Johansen, L. Iversen & K. Kragballe. (2010) Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement. British Journal of Dermatology 162:6, pages 1216-1223.
Crossref
Crossref
&NA;. (2009) Adalimumab: a guide to its use in plaque psoriasis. Drugs & Therapy Perspectives 25:7, pages 6-9.
Crossref
Crossref
Katherine F Croom & Paul L McCormack. (2009) Adalimumab. American Journal of Clinical Dermatology 10:1, pages 43-50.
Crossref
Crossref
G.A. Vena, A. Galluccio, C. De Simone, V. Mastrandrea, R. Buquicchio, S. La Greca, S. DattolaA. Puglisi Guerra, L. Donato, F. Cantoresi, O. De Pità, M. Pezza, M. D'Agostino, R. VernaciA. MiracapilloG. Valenti & N. Cassano. (2009) A Multicenter Open-Label Experience on the Response of Psoriasis to Adalimumab and Effect of Dose Escalation in Non-Responders: The Aphrodite Project. International Journal of Immunopathology and Pharmacology 22:1, pages 227-233.
Crossref
Crossref
Josep Manel Casanova, Verónica Sanmartín, Leandro Abal, Marta Ferran, Ramon M. Pujol & Miquel Ribera. (2008) Tratamiento de la psoriasis moderada y grave con adalimumab. Piel 23:10, pages 577-581.
Crossref
Crossref
M.K.A. Basra, R. Fenech, R.M. Gatt, M.S. Salek & A.Y. Finlay. (2008) The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. British Journal of Dermatology.
Crossref
Crossref